oncology

Showing 15 posts of 328 posts found.

Breast cancer cells can be transformed into fat cells using combination therapy, study shows

January 16, 2019
Research and Development Cancer, EMT, breast cancer, cells, oncology, tumours

An innovative cancer treatment can turn malignant breast cancer cells into fat cells, thus preventing the formation of metastases (the …

Tumours with large number of mutations respond better to immunotherapies, study shows

January 15, 2019
Manufacturing and Production, Research and Development Cancer, immunotherapy, nature, oncology, research, tumour

Tumours with a large number of DNA mutations are more likely to respond to immunotherapies than cancers with fewer mutations, …

novartis_outside_1

Dutch health minister attacks Novartis over orphan drug price hike

January 15, 2019
Manufacturing and Production Cancer, Lutathera, NL, Netherlands, Novartis, oncology

Dutch health minister Bruno Bairns has called for a meeting with Swiss multinational Novartis after the multibillion-dollar firm introduced a …

jose_baselga

AstraZeneca hire controversial cancer doc to head new Oncology R&D unit

January 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, journal, oncology

The Anglo-Swedish multinational AstraZeneca has named Dr José Baselga as the firm’s new head of research and development in oncology.The …

cancer-vs-alzheimer-1080x810

Roche’s Genentech inks potential $2bn personalised cancer drug development deal

January 7, 2019
Sales and Marketing Adaptive Biotechnologies, Cancer, Genentech, Roche, oncology, pharma

Roche’s Genentech is set to enter into a deal with Adaptive Biotechnologies to bolster its pursuits in the treatment of …

gilead-sciences

Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus

December 21, 2018
Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology

California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …

Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million

December 20, 2018
Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology

German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …

astrazeneca_plaque

AstraZeneca scores hat trick in ovarian cancer and anaemia clinical trials

December 20, 2018
Research and Development AstraZeneca, anaemia, oncology, ovarian cancer, pharma

Anglo-Swedish multinational AstraZeneca has revealed that its ovarian cancer drug (Lynparza) and anaemia treatment (Roxadustat) have met their goals in …

yorkshire_moors_dales_yorkshire_landscape_england_countryside_english_rural-497670

Those living in rural areas less likely to survive cancer, study shows

December 13, 2018
Medical Communications, Research and Development Cancer, health, oncology, rural, survival, urban

Those living in rural areas are less likely to survive cancer than their city dwelling counterparts, according to new research …

Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m

December 12, 2018
Research and Development Cancer, Oxford Biotherapeutics, WuXi Biologics, alliance, deal, oncology

Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in …

Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials

December 11, 2018
Manufacturing and Production, Sales and Marketing Cancer, breast cancer, clinical trials, global data, oncology

Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData. The drug, …

AstraZeneca

AstraZeneca’s head and neck cancer treatment Imfinzi falls flat in Phase III trials

December 7, 2018
Medical Communications AstraZeneca, Cancer, oncology, phase III, treatment

AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase …

GSK to acquire oncology biotech Tesaro for $5.1 billion

December 3, 2018
Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma

GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …

fda2outsideweb

FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi

November 27, 2018
Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma

The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …

boehringer_biberach_germany_copy

Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment

November 16, 2018
Medical Communications Boehringer, Cancer, Epizyme, deal, oncology

German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, …

The Gateway to Local Adoption Series

Latest content